Device Therapy and Cardiac Transplantation for End-Stage Heart Failure

Current Problems in Cardiology

Volumn 35, Issue 1, 2010, Pages 8-64

  Boilson, Barry A ^a   Raichlin, Eugenia ^a   Park, Soon J ^a   Kushwaha, Sudhir S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CLENBUTEROL; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; OKT 3; PLACEBO; PREDNISONE; PSEUDOMONIC ACID; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL HEART; BONE MARROW SUPPRESSION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOPULMONARY BYPASS; CELL THERAPY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUNTERPULSATION; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DEVICE THERAPY; DONOR SELECTION; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GRAFT FAILURE; GRAFT RECIPIENT; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LABORATORY TEST; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; ORGAN DONOR; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PREVALENCE; PROGNOSIS; SKIN CANCER; SOLID TUMOR; STAPHYLOCOCCUS INFECTION; SURGICAL TECHNIQUE; TOXOPLASMOSIS; TREATMENT INDICATION; WOUND HEALING IMPAIRMENT; XENOTRANSPLANTATION;

GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HEART, ARTIFICIAL; HEART-ASSIST DEVICES; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PREVALENCE; TISSUE DONORS;

EID: 70749149441     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2009.09.001     Document Type: Article

References (298)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics, 2009 update. A report from the american heart association statistics committee and stroke statistics subcommittee. Circulation 119 (2009) e21-e181
2. Miller L.W., and Missov E.D. Epidemiology of heart failure. Cardiol Clin 19 (2001) 547-555
3. Juonala M., Viikari J.S., Rasanen L., et al. Young adults with family history of coronary heart disease have increased arterial vulnerability to metabolic risk factors: the cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol 26 (2006) 1376-1382
4. Park S.J., Tector A., Piccioni W., et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 129 (2005) 9-17
5. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
6. Hershberger R.E., Nauman D., Walker T.L., et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory end stage heart failure. J Card Fail 9 (2003) 180-187
7. Fang J., Mensah G.A., Croft J.B., et al. Heart failure-related hospitalization in the U.S., 1979-2004. J Am Coll Cardiol 52 (2008) 428-434
8. Garrett N., and Martini E.M. The boomers are coming: a total cost of care model of the impact of population aging on the cost of chronic conditions in the United States. Dis Manag 10 (2007) 51-60
9. Kirklin J.K., and Naftel D.C. Mechanical circulatory support registering a therapy in evolution circulation. Heart Fail 1 (2008) 200-205
10. Shumacker Jr. H.B. A surgeon to remember: notes about Vladimir Demikhov. Ann Thorac Surg 58 (1994) 1196-1198
11. Marasco S.F., Lukas G., McDonald M., et al. Review of ECMO (Extra Corporeal Membrane Oxygenation) support in critically ill adult patients. Heart Lung Circul 17 suppl 4 (2008) S41-S47
12. Rajdev S., Irani A., Sharma S., et al. Clinical utility of TandemHeart for high-risk tandem procedures: percutaneous balloon aortic valvuloplasty followed by complex PCI. J Invasive Cardiol 19 (2007) E346-E349
13. Cohen R., Domniez T., and Elhadad S. High-risk left main coronary stenting supported by percutaneous Impella recover LP 2.5 assist device. J Invasive Cardiol 19 (2007) E294-E296
14. Burzotta F., Paloscia L., Trani C., et al. Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study. J Cardiovasc Med 9 (2008) 1004-1010
15. Thiele H., Sick P., Boudriot E., et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 26 (2005) 1276-1283
16. Seyfarth M., Sibbing D., Bauer I., et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52 (2008) 1584-1588
17. Rossiter-Thornton M., Arun V., Forrest A.P., et al. Left ventricular support with the Impella LP 5.0 for cardiogenic shock following cardiac surgery. Heart Lung Circul 17 (2008) 243-245
18. Saeed D., Kizner L., Arusoglu L., et al. Prolonged transcutaneous cardiopulmonary support for postcardiotomy cardiogenic shock. ASAIO J 53 (2007) e1-e3
19. John R., Liao K., Lietz K., et al. Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg 134 (2007) 351-358
20. De Robertis F., Rogers P., Amrani M., et al. Bridge to decision using the Levitronix CentriMag short-term ventricular assist device. J Heart Lung Transplant 27 (2008) 474-478
21. Dekkers R.J., Fitzgerald D.J., and Couper G.S. Five-year clinical experience with Abiomed BVS 5000 as a ventricular assist device for cardiac failure. Perfusion 16 (2001) 13-18
22. Mielniczuk L., da Silva L.B., and Haddad H. Enhanced external counterpulsation in ischemic heart disease and congestive heart failure. CMAJ 170 (2004) 1223-1224
23. Feldman A.M., Silver M.A., Francis G.S., et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 48 (2006) 1198-1205
24. Feldman A.M., Silver M.A., Francis G.S., et al. Treating heart failure with enhanced external counterpulsation (EECP): design of the prospective evaluation of EECP in heart failure (PEECH) trial. J Card Fail 11 (2005) 240-245
25. Lee C.M., Wu Y.W., Jui H.Y., et al. Enhanced external counterpulsation reduces lung/heart ratio at stress in patients with coronary artery disease. Cardiology 106 (2006) 237-240
26. Abbottsmith C.W., Chung E.S., Varricchione T., et al. Enhanced external counterpulsation improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trial. Congest Heart Fail 12 (2006) 307-311
27. Conti C.R. Ongoing and planned studies of enhanced external counterpulsation. Clin Cardiol 25 (2002) II26-II28
28. Birks E.J., Yacoub M.H., Banner N.R., et al. The role of bridge to transplantation: should LVAD patients be transplanted?. Curr Opin Cardiol 19 (2004) 148-153
29. Ekser B., Rigotti P., Gridelli B., et al. Xenotransplantation of solid organs in the pig-to-primate model. Transpl Immunol 21 (2008) 87-92
30. McCarthy P.M., James K.B., Savage R.M., et al. Implantable left ventricular assist device. Approaching an alternative for end-stage heart failure. Implantable LVAD Study Group. Circulation 90 (1994) II83-II86
31. Nose Y. Implantable total artificial heart developed by Abiomed gets FDA approval for clinical trials. Artif Organs 25 (2001) 429
32. Kantrowitz A., Krakauer J., and Sherman Jr. J.L. A permanent mechanical auxiliary ventricle: experimental and clinical experience. J Cardiovasc Surg 9 (1968) 1-16
33. Lietz K., Long J.W., Kfoury A.G., et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 116 (2007) 497-505
34. Hunt S.A. Mechanical circulatory support: new data, old problems. Circulation 116 (2007) 461-462
35. Stevenson L.W., Miller L.W., Desvigne-Nickens P., et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 110 (2004) 975-981
36. Rogers J.G., Butler J., Lansman S.L., et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 50 (2007) 741-747
37. Radovancevic B., Vrtovec B., de Kort E., et al. End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart Lung Transplant 26 (2007) 815-818
38. Houghton P. Living with the Jarvik 2000: a five-plus year experience. Artif Organs 30 (2006) 322-323
39. Pae W.E., Connell J.M., Adelowo A., et al. Does total implantability reduce infection with the use of a left ventricular assist device?. The LionHeart experience in Europe. J Heart Lung Transplant 26 (2007) 219-229
40. Dang N.C., Topkara V.K., Mercando M., et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant 25 (2006) 1-6
41. Matthews J.C., Koelling T.M., Pagani F.D., et al. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 51 (2008) 2163-2172
42. Slaughter M.S., Tsui S.S., El-Banayosy A., et al. Results of a multicenter clinical trial with the Thoratec implantable ventricular assist device. J Thorac Cardiovasc Surg 133 (2007) 1573-1580
43. Feldman C.M., Khan S.N., Slaughter M.S., et al. Improvement in early oxygen uptake kinetics with left ventricular assist device support. ASAIO J 54 (2008) 406-411
44. Etz C.D., Welp H.A., Tjan T.D., et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 83 (2007) 1697-1705
45. Wray J., Hallas C.N., and Banner N.R. Quality of life and psychological well-being during and after left ventricular assist device support. Clin Transpl 21 (2007) 622-627
46. Casida J. The lived experience of spouses of patients with a left ventricular assist device before heart transplantation. Am J Crit Care 14 (2005) 145-151
47. Shapiro P.A. Psychiatric aspects of cardiovascular disease. Psychiatr Clin North Am 19 (1996) 613-629
48. Zierer A., Melby S.J., Voeller R.K., et al. Late-onset driveline infections: the Achilles' heel of prolonged left ventricular assist device support. Ann Thorac Surg 84 (2007) 515-520
49. Schulman A.R., Martens T.P., Christos P.J., et al. Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices. J Thorac Cardiovasc Surg 133 (2007) 841-842
50. Letsou G.V., Shah N., Gregoric I.D., et al. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 24 (2005) 105-109
51. Geisen U., Heilmann C., Beyersdorf F., et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardio Thorac Surg 33 (2008) 679-684
52. Steinlechner B., Dworschak M., Birkenberg B., et al. Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg 87 (2009) 131-137
53. John R., Kamdar F., Liao K., et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg 136 (2008) 1318-1323
54. John R., Kamdar F., Liao K., et al. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg 86 (2008) 1227-1234 [Discussion 1234-5]
55. Slaughter M.S., Sobieski M.A., Gallagher C., et al. Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. Tex Heart Inst J 35 (2008) 245-249
56. Guha A., Munjampalli S., Bandi V., et al. Pleural effusion after ventricular assist device placement: prevalence and pleural fluid characteristics. Chest 134 (2008) 382-386
57. Joyce L.D., DeVries W.C., Hastings W.L., et al. Response of the human body to the first permanent implant of the Jarvik-7 total artificial heart. Trans Am Soc Artif Intern Organs 29 (1983) 81-87
58. Copeland J.G., Smith R.G., Arabia F.A., et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 351 (2004) 859-867
59. Samuels L., Entwistle J., Holmes E., et al. Use of the AbioCor replacement heart as destination therapy for end-stage heart failure with irreversible pulmonary hypertension. J Thorac Cardiovasc Surg 128 (2004) 643-645
60. Dowling R.D., Gray Jr. L.A., Etoch S.W., et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg 127 (2004) 131-141
61. Meyns B., Ector J., Rega F., et al. First human use of partial left ventricular heart support with the Circulite synergy micro-pump as a bridge to cardiac transplantation. Eur Heart J 29 (2008) 2582
62. Klotz S., Barbone A., Reiken S., et al. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol 45 (2005) 668-676
63. Barbone A., Holmes J.W., Heerdt P.M., et al. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation 104 (2001) 670-675
64. Heerdt P.M., Holmes J.W., Cai B., et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102 (2000) 2713-2719
65. Burkhoff D., Holmes J.W., Madigan J., et al. Left ventricular assist device-induced reverse ventricular remodeling. Prog Cardiovasc Dis 43 (2000) 19-26
66. DiBardino D.J. The history and development of cardiac transplantation. Tex Heart Inst J 26 (1999) 198-205
67. Carrel A., and Guthrie C.C. Anastomosis of blood vessels by the patching method and transplantation of the kidney. 1906 (Classical article). Yale J Biol Med 74 (2001) 243-247
68. Mann F.C., Priestly J.T., Markowitz J., et al. Transplantation of the intact mammalian heart. Arch Surg 26 (1933) 219-224
69. Willman V.L., Cooper T., Cian L.G., et al. Auto-transplantation of the canine heart. Surg Gynecol Obstet 115 (1962) 299-302
70. Barnard C.N. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 41 (1967) 1271-1274
71. Rodeheffer R.J., and McGregor C.G. The development of cardiac transplantation. Mayo Clin Proc 67 (1992) 480-484
72. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the international society for heart and lung transplantation. Twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 26 (2007) 769-781
73. Taylor D.O., Edwards L.B., Aurora P., et al. Registry of the international society for heart and lung transplantation. Twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 27 (2008) 943-956
74. Lietz K., and Miller L.W. Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990-2005. J Am Coll Cardiol 50 (2007) 1282-1290
75. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
76. Borkon A.M., Muehlebach G.F., Jones P.G., et al. An analysis of the effect of age on survival after heart transplant. J Heart Lung Transplant 18 (1999) 668-674
77. Morgan J.A., John R., Weinberg A.D., et al. Long-term results of cardiac transplantation in patients 65 years of age and older: a comparative analysis. Ann Thorac Surg 76 (2003) 1982-1987
78. Nwakanma L.U., Williams J.A., Weiss E.S., et al. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 84 (2007) 1556-1562 [Discussion 1562-3]
79. Zangwill S., Ellis T., Stendahl G., et al. Practical application of the virtual crossmatch. Pediatr Transplant 11 (2007) 650-654
80. Betkowski A.S., Graff R., Chen J.J., et al. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant 21 (2002) 644-650
81. Loh E., Bergin J.D., Couper G.S., et al. Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation. J Heart Lung Transplant 13 (1994) 194-201
82. Leech S.H., Lopez-Cepero M., LeFor W.M., et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transpl 20 (2006) 476-484
83. Lavee J., Kormos R.L., Duquesnoy R.J., et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 10 (1991) 921-929 [Discussion 929-30]
84. Lenexa K. Standards for histocompatibility testing (1998), American Society for Histocompatibility and Immunogenetics, Lenexa, Kansas
85. UNOS. The United Network for Organ Sharing. Standards for histocompatibility testing. 1998. ByLaws Appendix B Attachment JJA, www.unos.org/policiesandbylaws/bylaws.
86. Shumway N.E., Lower R.R., and Stofer R.C. Transplantation of the heart. Adv Surg 2 (1966) 265-284
87. Jacquet L., Ziady G., Stein K., et al. Cardiac rhythm disturbances early after orthotopic heart transplantation: prevalence and clinical importance of the observed abnormalities. J Am Coll Cardiol 16 (1990) 832-837
88. Angermann C.E., Spes C.H., Tammen A., et al. Anatomic characteristics and valvular function of the transplanted heart: transthoracic versus transesophageal echocardiographic findings. J Heart Transplant 9 (1990) 331-338
89. Banner N.R., Khaghani A., and Fitzgerald M. The Expanding Role of Cardiac Transplantation. Assisted Circulation (1989), Springer-Verlag, Berlin
90. Yacoub M.H., and Banner N.A. Recent Development in Lung and Heart-Lung Transplantation. Transplantation Reviews vol 3 (1989), WB Saunders, Philadelphia, PA 1-29
91. Aziz T.M., Burgess M.I., El-Gamel A., et al. Orthotopic cardiac transplantation technique: a survey of current practice. Ann Thorac Surg 68 (1999) 1242-1246
92. Drefus G., Jebara V., Mihaileaunu S., et al. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg 52 (1991) 1181-1184
93. Sievers H.H., Weyand M., Kraatz E.G., et al. An alternative technique for orthotopic cardiac transplantation, with preservation of the normal anatomy of the right atrium. J Thorac Cardiovasc Surg 39 (1991) 70-72
94. Schnoor M., Schafer T., Luhmann D., et al. Bicaval versus standard technique in orthotopic heart transplantation: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 134 (2007) 1322-1331
95. Uber P.A., and Mehra M.R. Induction therapy in heart transplantation: is there a role?. J Heart Lung Transplant 26 (2007) 205-209
96. Opelz G., Schwarz V., Henderson R., et al. Non-Hodgkin's lymphoma after kidney or heart transplantation: frequency of occurrence during the first posttransplant year. Transpl Int 7 suppl 1 (1994) S353-S356
97. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323 (1990) 1723-1728
98. Higgins R., Kirklin J.K., Brown R.N., et al. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?. J Heart Lung Transplant 24 (2005) 392-400
99. Crespo-Leiro M.G., Alonso-Pulpon L., Arizon J.M., et al. Influence of induction therapy, immunosuppressive regimen and antiviral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry. J Heart Lung Transplant 26 (2007) 1105-1109
100. Segovia J., Rodriguez-Lambert J.L., Crespo-Leiro M.G., et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation 81 (2006) 1542-1548
101. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 24 (2005) 1297-1304
102. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352 (2005) 2705-2713
103. Grimm M., Rinaldi M., Yonan N.A., et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 6 (2006) 1387-1397
104. Kobashigawa J.A., Patel J., Furukawa H., et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 25 (2006) 434-439
105. Hosenpud J.D., and Bennett L.E. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 72 (2001) 1662-1665
106. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66 (1998) 507-515
107. Kobashigawa J.A., and Meiser B.M. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 80 (2005) S235-S243
108. Pethig K., Heublein B., Wahlers T., et al. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant 23 (2004) 61-66
109. Lietz K., John R., Schuster M., et al. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc 34 (2002) 1828-1829
110. Weigel G., Griesmacher A., Karimi A., et al. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant 21 (2002) 1074-1079
111. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
112. Patel J.K., and Kobashigawa J.A. Tacrolimus in heart transplant recipients: an overview. Biodrugs 21 (2007) 139-143
113. Aguero J., Almenar L., Martinez-Dolz L., et al. Variations in the frequency and type of infections in heart transplantation according to the immunosuppression regimen. Transplant Proc 38 (2006) 2558-2559
114. Dumont F.J., Staruch M.J., Koprak S.L., et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144 (1990) 251-258
115. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 (2003) 7S-14S
116. Terada N., Lucas J.J., Szepesi A., et al. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 154 (1993) 7-15
117. Morales J.M., Andres A., Rengel M., et al. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 16 (2001) 121-124
118. Shihab F.S., Bennett W.M., Yi H., et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65 (2004) 1262-1271
119. Kushwaha S.S., Khalpey Z., Frantz R.P., et al. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 24 (2005) 2129-2136
120. Raichlin E., Khalpey Z., Kremers W., et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 84 (2007) 467-474
121. Raichlin E., Bae J.H., Khalpey Z., et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116 (2007) 2726-2733
122. McMullen J.R., Sherwood M.C., Tarnavski O., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109 (2004) 3050-3055 [Epub 2004 June 7]
123. Hauck L., Harms C., Rohne J., et al. Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med 14 (2008) 315-324 [Epub 2008 March 2]
124. Doggrell S.A. Cardiovascular research in Australia. Drug News Perspect 16 (2003) 540-550
125. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
126. Hill J.A., Hummel M., Starling R.C., et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 84 (2007) 1436-1442
127. Webster A.C., Lee V.W., Chapman J.R., et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234-1248
128. Bestetti R., Theodoropoulos T.A.D., Burdmann E.A., et al. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 81 (2006) 692-696
129. Groetzner J., Kaczmarek I., Landwehr P., et al. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardio Thorac Surg 25 (2004) 333-341
130. Knight R.J., Villa M., Laskey R., et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transpl 21 (2007) 460-465
131. Dean P.G., Lund W.J., Larson T.S., et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77 (2004) 1555-1561
132. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
133. Troppmann C., Pierce J.L., Gandhi M.M., et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 76 (2003) 426-429
134. Michaels P.J., Espejo M.L., Kobashigawa J., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22 (2003) 58-69
135. Yamani M.H., Yousufuddin M., Starling R.C., et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy?. J Heart Lung Transplant 23 (2004) 272-276
136. Deng M.C., Eisen H.J., Mehra M.R., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6 (2006) 150-160
137. Starling R.C., Pham M., Valantine H., et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant 25 (2006) 1389-1395
138. Pham M.X., Deng M.C., Kfoury A.G., et al. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the invasive monitoring attenuation through gene expression (IMAGE) trial. J Heart Lung Transplant 26 (2007) 808-814
139. Taylor D.O., Yowell R.L., Kfoury A.G., et al. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 19 (2000) 518-521
140. Uber W.E., Self S.E., Van Bakel A.B., et al. Acute antibody-mediated rejection following heart transplantation. Am J Transplant 7 (2007) 2064-2074
141. Tan C.D., Baldwin III W.M., and Rodriguez E.R. Update on cardiac transplantation pathology. Arch Pathol Lab Med 131 (2007) 1169-1191
142. Smith R.N., Brousaides N., Grazette L., et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 24 (2005) 1202-1210
143. Almuti K., Haythe J., Dwyer E., et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation 84 (2007) 498-503
144. Roelke M., McNamara D., Osswald S., et al. A comparison of VVIR and DDDR pacing following cardiac transplantation. Pacing Clin Electrophysiol 17 (1994) 2047-2051
145. Rothenburger M., Teerling E., Bruch C., et al. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant 26 (2007) 250-257
146. Hertz M.I., Taylor D.O., Trulock E.P., et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant 21 (2002) 950-970
147. Kapadia S.R., Ziada K.M., L'Allier P.L., et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. J Heart Lung Transplant 19 (2000) 167-172
148. Boilson B.A., and McGregor C.G. Stem cells and transplant vasculopathy. Minerra Cardioangiol 57 (2009) 233-247 Review
149. Kuppahally S.S., Valantine H.A., Weisshaar D., et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant 7 (2007) 2388-2395
150. Kobashigawa J.A. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant 22 (2003) 711-714
151. Caforio A.L., Tona F., Fortina A.B., et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 4 (2004) 962-970
152. Bernstein D., Kolla S., Miner M., et al. Cardiac growth after pediatric heart transplantation. (see comments). Circulation 85 (1992) 1433-1439
153. Adams D.H., Russell M.E., Hancock W.W., et al. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev 134 (1993) 5-19
154. Jimenez J., Kapadia S.R., Yamani M.H., et al. Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. J Heart Lung Transplant 20 (2001) 393-398
155. Brunner-La Rocca H.P., Schneider J., Kunzli A., et al. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation 65 (1998) 538-543
156. Raichlin E., Edwards B., Kremers W., et al. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J Heart Lung Transplant 28 (2009) 320-327
157. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients. The collaborative transplant study. Transplant Proc 29 (1997) 73-76
158. Narrod J., Kormos R., Armitage J., et al. Acute rejection and coronary artery disease in long-term survivors of heart transplantation. J Heart Transplant 8 (1989) 418-420 [Discussion 420-1]
159. Vassalli G., Gallino A., Weis M., et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 24 (2003) 1180-1188
160. Yamani M.H., Haji S.A., Starling R.C., et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 39 (2002) 970-977
161. Stoica S.C., Cafferty F., Pauriah M., et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 25 (2006) 420-425
162. Hognestad A., Endresen K., Wergeland R., et al. Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol 42 (2003) 477-482
163. Pethig K., Heublein B., Kutschka I., et al. Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 102 (2000) III233-III236
164. Raichlin E., McConnell J.P., Bae J.H., et al. Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation 85 (2008) 963-968
165. Raichlin E.R., McConnell J.P., Lerman A., et al. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. J Heart Lung Transplant 26 (2007) 826-833
166. Lerman A., and Zeiher A.M. Endothelial function: cardiac events. Circulation 111 (2005) 363-368
167. Raichlin E., Kushwaha S.S., Lennon R.J., et al. Features of cardiac allograft coronary endothelial dysfunction. Am J Cardiol 103 (2009) 1154-1158
168. Hollenberg S.M., Klein L.W., Parrillo J.E., et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 104 (2001) 3091-3096
169. Davis S.F., Yeung A.C., Meredith I.T., et al. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year posttransplant. Circulation 93 (1996) 457-462
170. Sudhir K., MacGregor J.S., DeMarco T., et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 90 (1994) 3018-3023
171. Abraham R.T., Karnitz L.M., Burns L.A., et al. Proximal signals and the control of S-phase entry in interleukin-2-stimulated T lymphocytes. Adv Exp Med Biol 365 (1994) 197-210
172. Edwards B.S., Hunt S.A., Fowler M.B., et al. Effect of cyclosporine on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol 67 (1991) 782-784
173. Diederich D., Skopec J., Diederich A., et al. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 23 (1994) 957-961
174. Diederich D., Yang Z., and Luscher T.F. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 2 (1992) 1291-1297
175. Rubin R.H. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J Am Med Assoc 261 (1989) 3607-3609
176. Koskinen P.K., Nieminen M.S., Krogerus L.A., et al. Cytomegalovirus infection accelerates cardiac allograft vasculopathy: correlation between angiographic and endomyocardial biopsy findings in heart transplant patients. Transpl Int 6 (1993) 341-347
177. Sia I.G., and Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 13 (2000) 83-121 [table of contents]
178. Hussain T., Burch M., Fenton M.J., et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 115 (2007) 1798-1805
179. Bonaros N.E., Kocher A., Dunkler D., et al. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. Transplantation 77 (2004) 890-897
180. Zakliczynski M., Krynicka-Mazurek A., Pyka L., et al. The influence of cytomegalovirus infection, confirmed by pp65 Antigen presence, on the development of cardiac allograft vasculopathy. Transplant Proc 39 (2007) 2866-2869
181. Ramzy D., Rao V., Brahm J., et al. Cardiac allograft vasculopathy: a review. Can J Surg 48 (2005) 319-327
182. Gao S.Z., Alderman E.L., Schroeder J.S., et al. Progressive coronary luminal narrowing after cardiac transplantation. Circulation 82 (1990) IV269-IV275
183. Julius B.K., Attenhofer Jost C.H., Sutsch G., et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after heart transplantation. Transplantation 69 (2000) 847-853
184. Rickenbacher P.R., Pinto F.J., Chenzbraun A., et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 25 (1995) 171-177
185. Kushwaha S.S., Narula J., Narula N., et al. Pattern of changes over time in myocardial blood flow and microvascular dilator capacity in patients with normally functioning cardiac allografts. Am J Cardiol 82 (1998) 1377-1381
186. Sharples L.D., Jackson C.H., Parameshwar J., et al. Diagnostic accuracy of coronary angiography and risk factors for post-heart-transplant cardiac allograft vasculopathy. Transplantation 76 (2003) 679-682
187. Klauss V., Mudra H., Uberfuhr P., et al. Intraindividual variability of cardiac allograft vasculopathy as assessed by intravascular ultrasound. Am J Cardiol 76 (1995) 463-466
188. Amital A., Shitrit D., Raviv Y., et al. Development of malignancy following lung transplantation. Transplantation 81 (2006) 547-551
189. Fedak P.W., Rao V., Verma S., et al. Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. J Thorac Cardiovasc Surg 129 (2005) 407-415
190. Ross H., Hendry P., Dipchand A., et al. Canadian Cardiovascular Society Consensus Conference on Cardiac Transplantation. Can J Cardiol 19 (2003) 620-654
191. Nair A., Kuban B.D., Tuzcu E.M., et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106 (2002) 2200-2206
192. Nair A., Kuban B.D., Obuchowski N., et al. Assessing spectral algorithms to predict atherosclerotic plaque composition with normalized and raw intravascular ultrasound data. Ultrasound Med Biol 27 (2001) 1319-1331
193. Nasu K., Tsuchikane E., Katoh O., et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 47 (2006) 2405-2412 [Epub 2006 May 30]
194. Raichlin E., Bae J.H., Kushwaha S.S., et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol 53 (2009) 1279-1286
195. Massy Z.A., Guijarro C., Wiederkehr M.R., et al. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 49 (1996) 518-524
196. Miyagawa-Hayashino A., Tsuruyama T., Haga H., et al. Arteriopathy in chronic allograft rejection in liver transplantation. Liver Transplant 10 (2004) 513-519
197. Bacon C.R., and Davenport A.P. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol 117 (1996) 986-992
198. Pamboukian S.V., and Costanzo M.R. Transplant coronary vasculopathy. Curr Treat Options Cardiovasc Med 3 (2001) 55-63
199. Bolad I.A., Robinson D.R., Webb C., et al. Impaired left ventricular systolic function early after heart transplantation is associated with cardiac allograft vasculopathy. Am J Transplant 6 (2006) 161-168
200. Benza R.L., Zoghbi G.J., Tallaj J., et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol 43 (2004) 1973-1981
201. Jonas M., Fang J.C., Wang J.C., et al. In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol 48 (2006) 453-461 [Epub 2006 July 12]
202. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
203. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 107 (2003) 93-97
204. Mehra M.R., Ventura H.O., Smart F.W., et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 75 (1995) 853-854
205. Schroeder J.S., Gao S.Z., Alderman E.L., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 328 (1993) 164-170
206. Fang J.C., Kinlay S., Beltrame J., et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 359 (2002) 1108-1113
207. Shirakawa I., Sata M., Saiura A., et al. Atorvastatin attenuates transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Biomed Pharmacother 61 (2007) 154-159
208. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a trial of pravastatin in heart transplant recipients. J Heart Lung Transplant 24 (2005) 1736-1740
209. Sipahi I., and Starling R.C. Cardiac allograft vasculopathy: an update. Heart Fail Clin 3 (2007) 87-95
210. Segovia J., Gomez-Bueno M., and Alonso-Pulpon L. Treatment of allograft vasculopathy in heart transplantation. Exp Opin Pharmacother 7 (2006) 2369-2383
211. Lubitz S.A., Pinney S., Wisnivesky J.P., et al. Statin therapy associated with a reduced risk of chronic renal failure after cardiac transplantation. J Heart Lung Transplant 26 (2007) 264-272
212. Raichlin E., Bae J.H., Khalpey Z., et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116 (2007) 2726-2733
213. Mudge Jr. G.H. Sirolimus and cardiac transplantation: is it the "magic bullet"?. Circulation 116 (2007) 2666-2668
214. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 (2004) 2694-2700
215. Raichlin E., Prasad A., Kremers W.K., et al. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared to calcineurin-inhibitors in stable cardiac transplant recipients. Eur Heart J 30 (2009) 1356-1363
216. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
217. Raichlin E., Bae J.H., Kushwaha S.S., et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol 53 (2009) 1279-1286
218. Lobach N.E., Pollock-Barziv S.M., West L.J., et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 24 (2005) 184-189
219. Walker K., Skelton H., and Smith K. Cutaneous lesions showing giant yeast forms of Blastomyces dermatitidis. J Cutan Pathol 29 (2002) 616-618
220. Masri K., Mahon N., Rosario A., et al. Reactive hemophagocytic syndrome associated with disseminated histoplasmosis in a heart transplant recipient. J Heart Lung Transplant 22 (2003) 487-491
221. Jastrzebski D., Zakliczynski M., Siola M., et al. Lower respiratory tract infections in patients during hospital stay after heart transplantation. Ann Transplant 8 (2003) 37-39
222. Kendall J.B., Hart C.A., Pennefather S.H., et al. Infection control measures for adult cardiac surgery in the UK-a survey of current practice. J Hosp Infect 54 (2003) 174-178
223. Kriaras I., Michalopoulos A., Turina M., et al. Evolution of antimicrobial prophylaxis in cardiovascular surgery. Eur J Cardio Thorac Surg 18 (2000) 440-446
224. Parry G.W., Holden S.R., and Shabbo F.P. Antibiotic prophylaxis for cardiac surgery: current United Kingdom practice. Br Heart J 70 (1993) 585-586
225. Casewell M.W. The nose: an underestimated source of Staphylococcus aureus causing wound infection. J Hosp Infect 40 suppl B (1998) S3-S11
226. Cimochowski G.E., Harostock M.D., Brown R., et al. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 71 (2001) 1572-1578 [Discussion 1578-9]
227. Pescovitz M.D. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 82 (2006) S4-S8
228. Potena L., Holweg C.T., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82 (2006) 398-405
229. Noble S., and Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56 (1998) 115-146
230. Cooper D.K., Novitzky D., Schlegel V., et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant 10 (1991) 656-662 [Discussion 662-3]
231. Couchoud C., Cucherat M., Haugh M., et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 65 (1998) 641-647
232. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antivir Res 71 (2006) 154-163
233. Nankivell B.J., Malouf M.A., Russ G.R., et al. Maintenance therapy with oral ganciclovir after treatment of cytomegalovirus infection. Clin Transpl 12 (1998) 270-273
234. Gane E., Saliba F., Valdecasas G.J., et al. Randomised Trial of Efficacy and Safety of Oral Ganciclovir in the Prevention of Cytomegalovirus Disease in Liver-Transplant Recipients. Oral Ganciclovir International Transplantation Study Group. [corrected]. Lancet 350 (1997) 1729-1733
235. Devyatko E., Zuckermann A., Ruzicka M., et al. Preemptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 23 (2004) 1277-1282
236. Baldanti F., Simoncini L., Sarasini A., et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 66 (1998) 324-329
237. Drew W.L., Paya C.V., and Cytomegalovirus E.V. (CMV) resistance to antivirals. Am J Transplant 1 (2001) 307-312
238. Limaye A.P., Corey L., Koelle D.M., et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356 (2000) 645-649
239. Razonable R.R., and Emery V.C. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes 11 (2004) 77-86
240. Fiddian P., Sabin C.A., and Griffiths P.D. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis 186 suppl 1 (2002) S110-S115
241. Baran D.A., Alwarshetty M.M., Alvi S., et al. Is toxoplasmosis prophylaxis necessary in cardiac transplantation?. Long-term follow-up at two transplant centers. J Heart Lung Transplant 25 (2006) 1380-1382
242. Fishman J.A. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 33 (2001) 1397-1405
243. Orr K.E., Gould F.K., Short G., et al. Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect 29 (1994) 249-253
244. Playford E.G., Webster A.C., Sorell T.C., et al. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev (2004) CD004291
245. Penn I. Cancers complicating organ transplantation. N Engl J Med 323 (1990) 1767-1769
246. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 61 (1996) 274-278
247. Dantal J., and Soulillou J.P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 352 (2005) 1371-1373
248. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
249. Veness M.J. Cardiac transplant-related cutaneous malignancies in an Australian recipient: immunosuppression, friend or foe?. Clin Oncol (R Coll Radiol) 10 (1998) 194-197
250. Veness M.J., Quinn D.I., Ong C.S., et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 85 (1999) 1758-1764
251. Lindelof B., Sigurgeirsson B., Gabel H., et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143 (2000) 513-519
252. Gjersvik P., Hansen S., Moller B., et al. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?. Transpl Int 13 suppl 1 (2000) S380-S381
253. Tiu J., Li H., Rassekh C., et al. Molecular basis of posttransplant squamous cell carcinoma: the potential role of cyclosporine A in carcinogenesis. Laryngoscope 116 (2006) 762-769
254. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
255. Kahan B.D., Knight R., Schoenberg L., et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 35 (2003) 25S-34S
256. Mathew T., Kreis H., and Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl 18 (2004) 446-449
257. Otley C.C., and Maragh S.L. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 31 (2005) 163-168
258. Otley C.C., Berg D., Ulrich C., et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 154 (2006) 395-400
259. Otley C.C., Griffin M.D., Charlton M.R., et al. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol 157 (2007) 1183-1188
260. Tavadia S., Dawn G., Payne C., et al. Skin-cancer awareness in Scottish cardiac transplant recipients. Clin Exp Dermatol 31 (2006) 354-357
261. Chen K., Craig J.C., and Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 152 (2005) 518-523
262. McNamara I.R., Muir J., and Galbraith A.J. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 21 (2002) 1201-1205
263. Goldstein D.J., Williams D.L., Oz M.C., et al. Novo solid malignancies after cardiac transplantation. Ann Thorac Surg 60 (1995) 1783-1789
264. Pham S.M., Kormos R.L., Landreneau R.J., et al. Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg 60 (1995) 1623-1626
265. Penn I. Tumors after renal and cardiac transplantation. Hematol/Oncol Clin North Am 7 (1993) 431-445
266. Penn I., Hammond W., Brettschneider L., et al. Malignant lymphomas in transplantation patients. Transplant Proc 1 (1969) 106-112
267. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1 (1984) 583-587
268. Borenstein J., Pezzella F., and Gatter K.C. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology 51 (2007) 774-777
269. Pitman S.D., Rowsell E.H., Cao J.D., et al. Anaplastic large cell lymphoma associated with Epstein-Barr virus following cardiac transplant. Am J Surg Pathol 28 (2004) 410-415
270. +, neutrophil-rich variant with subcutaneous panniculitic lesions, in a post-renal transplant patient: report of unusual case and literature review. Am J Dermatopathol 27 (2005) 217-223
271. Tsao L., Chu K.E., Bhagat G., et al. Development of hairy cell leukemia in a patient after cardiac transplantation. Leuk Lymph 47 (2006) 361-363
272. Tsao L., Draoua H.Y., Mansukhani M., et al. EBV-associated, extranodal NK-cell lymphoma, nasal type of the breast, after heart transplantation. Mod Pathol 17 (2004) 125-130
273. Nalesnik M.A., Jaffe R., Starzl T.E., et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133 (1988) 173-192
274. Birkeland S.A., and Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per SE?. Transplantation 76 (2003) 984-988
275. Gao S.Z., Chaparro S.V., Perlroth M., et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 22 (2003) 505-514
276. Aull M.J., Buell J.F., Trofe J., et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 78 (2004) 1676-1682
277. Leblond V., Davi F., Charlotte F., et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 16 (1998) 2052-2059
278. Dotti G., Fiocchi R., Motta T., et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 69 (2000) 827-833
279. Smith J.M., Corey L., Healey P.J., et al. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 83 (2007) 1423-1428
280. Cockfield S.M. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 3 (2001) 70-78
281. Darenkov I.A., Marcarelli M.A., Basadonna G.P., et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 64 (1997) 848-852
282. Davis C.L., Harrison K.L., McVicar J.P., et al. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transpl 9 (1995) 53-59
283. Preiksaitis J.K., Diaz-Mitoma F., Mirzayans F., et al. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 166 (1992) 986-994
284. Nart D., Nalbantgil S., Yagdi T., et al. Primary cardiac lymphoma in a heart transplant recipient. Transplant Proc 37 (2005) 1362-1364
285. Ouseph R., Denny D.M., and Erbeck K.M. Lymphoproliferative disease seen as a cardiac mass after orthotopic heart transplantation. J Am Soc Echocardiogr 11 (1998) 758-760
286. Bregman S.G., Yeaney G.A., Greig B.W., et al. Subcutaneous panniculitic T-cell lymphoma in a cardiac allograft recipient. J Cutan Pathol 32 (2005) 366-370
287. Samolitis N.J., Bharadwaj J.S., Weis J.R., et al. Post-transplant lymphoproliferative disorder limited to the skin. J Cutan Pathol 31 (2004) 453-457
288. Lamba M., Jabi M., Padmore R., et al. Isolated pleural PTLD after cardiac transplantation. Cardiovasc Pathol 11 (2002) 346-350
289. Rolland S.L., Seymour R.A., Wilkins B.S., et al. Post-transplant lymphoproliferative disorders presenting as gingival overgrowth in patients immunosuppressed with ciclosporin. A report of two cases. J Clin Periodontol 31 (2004) 581-585
290. Boilson B.A., Miller D.V., and Pereira N.L. Late allograft failure after heart transplantation: 2 unusual cases. J Heart Lung Transplant 27 (2008) 1050-1054
291. Siddiqui M.T., Reddy V.B., Castelli M.J., et al. Role of fine-needle aspiration in clinical management of transplant patients. Diagn Cytopathol 17 (1997) 429-435
292. Milpied N., Vasseur B., Parquet N., et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11 suppl 1 (2000) 113-116
293. Oertel S.H., Verschuuren E., Reinke P., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5 (2005) 2901-2906
294. Everly M.J., Bloom R.D., Tsai D.E., et al. Posttransplant lymphoproliferative disorder. Ann Pharmacother 41 (2007) 1850-1858
295. Haddad E., Paczesny S., Leblond V., et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 97 (2001) 1590-1597
296. Trappe R., Riess H., Babel N., et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 83 (2007) 912-918
297. Preiksaitis J.K. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis 39 (2004) 1016-1023
298. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110 (2007) 1123-1131